2012


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2012/№2

Диуретики: особенности применения при отечном синдроме и артериальной гипертензии

Рязанцева Е. Е., Мелехов А. В., Гендлин Г. Е.
ГБОУ ВПО "РНИМУ им. Н. И. Пирогова Минздравсоцразвития", 117997, Москва, ул. Островитянова, д. 1

Ключевые слова: артериальная гипертензия, диуретики, лечение, отеки, ХСН

DOI: 10.18087/rhfj.2012.2.1684

Диуретики позволяют уменьшить объем циркулирующей крови, а значит, снизить АД, давление в малом круге кровообращения и в воротной вене, уменьшить отеки. Препараты этой группы влияют на обмен воды и электролитов в организме человека, то есть их действие направлено на основные звенья патогенеза АГ и застойной сердечной недостаточности. В обзоре рассматриваются эффекты ранее известных мочегонных препаратов и новых дженерических.
  1. Stafford RS, Bartholomew LK, Cushman WC et al. ALLHAT Collaborative Research Group. Impact of the ALLHAT / JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med. 2010;170 (10):851–858.
  2. Ramsay LE. Thiazide diuretics in hypertension. Clin Exp Hypertens. 1999;21 (5-6):805–814.
  3. Chaturvedi S. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): is it really practical? Natl Med J India. 2004;17 (4):227.
  4. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001;24 (15):1155–1165.
  5. Biddle TL, Yu PN. Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction. Am J Cardiol. 1979;43 (1):86–90.
  6. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365 (9474):1877–1889.
  7. Vardas PE, Auricchio A, Blanc JJ et al., [Guidelines for cardiac pacing and cardiac resynchronization therapy]. Rev Port Cardiol. 2008;27 (5):639–687.
  8. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10 (10):933–989.
  9. Агеев Ф. Т., Арутюнов Г. П., Глезер М. Г. и др. Национальные Рекомендации ВНОК и ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2006;7 (2):52–80.
  10. Сторожаков Г. И., Гендлин Г. Е. Основные направления в лечении больных с хронической сердечной недостаточностью (руководство для врачей терапевтов врачей общей практики). – М.: Миклош. 2008. – 312 с.
  11. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris). 2000;61 (1):52–60.
  12. Pfister R, Schneider CA. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Eur Heart J. 2009;30 (3):382–383.
  13. Ghys A, Denef J, Delarge J, Georges A. Renal effects of the high ceiling diuretic torasemide in rats and dogs. Arzneimittelforschung. 1985;35 (10):1527–1531.
  14. Scheen AJ, Vancrombreucq JC, Delarge J, Luyckx AS. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol. 1986;31 (Suppl): 35–42.
  15. Broekhuysen J, Deger F, Douchamps J et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol. 1986;31 (Suppl): 29–34.
  16. Herchuelz, A., et al., Comparative pharmacodynamics of torasemide and furosemide in patients with oedema. Arzneimittelforschung, 1988. 38 (1A): p. 180–3.
  17. Uchida T, Yamanaga K, Nishikawa M et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205 (2):145–150.
  18. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390.
  19. Dodion L, Willems JL. Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency. Eur J Clin Pharmacol. 1986;31 (Suppl): 49–51.
  20. Brater DC, Rudy DR, Voelker JR et al. Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency – preliminary evaluation. Cardiovasc Drugs Ther. 1993;7 (Suppl 1):69–73.
  21. Achhammer I, Häcker W, Glocke M. Efficacy and safety of torasemide in patients with chronic heart failure. Arzneimittelforschung. 1988;38 (1A): 184–187.
  22. Wittig T, Medert G. [Torasemide in patients with chronic heart failure. Results of clinical administration in general practice]. Fortschr Med. 1996;114 (3):24–28.
  23. Cosín J, Díez J; TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513.
  24. Barbanoj MJ, Ballester MR, Antonijoan RM et al. A bioavailability / bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation. Clin Exp Pharmacol Physiol. 2009;36 (5-6):469–477.
  25. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV – efficacy and quality of life. Eur J Heart Fail. 2003;5 (6):793–801.
  26. Kasama S, Toyama T, Hatori T et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92 (10):1434–1440.
  27. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50 (9):859–867.
  28. TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study. Clin Ther. 2011;33 (9):1204–1213.e3.
  29. Spannheimer A, Goertz A, Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract. 1998;52 (7):467–471.
  30. Stroupe KT, Forthofer MM, Brater DC, Murray MD. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 2000;17 (5):429–440.
  31. Spannbrucker N, Achhammer I, Metz P et al. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Drug Res. 1988;38 (1):190–193.
  32. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41 (Suppl 3): 80–91.
  33. Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C et al. Torasemide-PR in Hypertension Clinical Trial Investigators Group Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther. 2008;26 (2):91–100.
  34. Applefeld JJ, Kasmer RJ, Hak LJ et al. A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis. Aliment Pharmacol Ther. 1994;8 (4):397–402.
  35. Boecker WH, KJ, Eberwein B. Efficacy and safety of torasemide (10–200 mg / day p.o.) in the treatment of edema in patients with nephrotic syndrome, in Diuretics IV: Chemistry, Pharmacology and Clinical Application. – P. JB, Editor. 1993: Elsevier. – p. 51–54.
  36. Russo D, Minutolo R, Andreucci VE. Role of loop diuretics in chronic renal failure. Cardiology. 1994;84 (Suppl 2):162–170.
  37. Franz M, Banyai-Falger S, Traindl O et al. Does torasemide reduce proteinuria in nephrotic patients? Nephrol Dial Transplant. 1996;11 (12):2521–2522.
Рязанцева Е.Е., Мелехов А.В., Гендлин Г.Е. Диуретики: особенности применения при отечном синдроме и артериальной гипертензии. Журнал Сердечная Недостаточность. 2012;13(2):105-110.

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En